Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹11.61 Cr |
| Reserved for Market Maker | ₹59.34 Cr |
| Net Issue Size | ₹11.61 Cr |
| Fresh Issue | ₹11.02 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹41.00-43.00 per share |
| BSE Code | 544759 |
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead Managers | Cumulative Capital Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 6,000 shares · Multiples of 3,000 shares
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:
The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.
All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.
The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company | 8.35 |
| 2 | General Corporate Purposes | 1.71 |
| 3 | Issue Expense | 1.55 |
| Total | 11.61 |
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
| Amount in ₹ Crore | ||||
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 21.02% | 35.83% |
| ROCE | 24.22% | 38.45% |
| Debt / Equity | 1.07% | 1.50% |
| RoNW | 17.99% | 27.37% |
| PAT Margin | 10.38% | 10.09% |
| EBITDA Margin | 19.41% | 20.78% |
| Price to Book Value | 3.47 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 4.11 | 3.09 |
| P/E (x) | 10.47 | 13.93 |
| Promoter Holding | 79.70% | 57.29% |
| Market Cap | ₹41.28 Cr. | |
